CI
NKTR icon

CX Institutional’s Nektar Therapeutics NKTR Stock Holding History

CX Institutional’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5
Closed -$1K – 892
2020
Q3 		$1K Hold
5
– – ﹤0.01% 855
2020
Q2 		$2K Buy
+5
New +$1.56K ﹤0.01% 756
2020
Q1 		– Sell
-6
Closed -$2K – 788
2019
Q4 		$2K Hold
6
– – ﹤0.01% 671
2019
Q3 		$2K Buy
6
+4
+200% +$1.47K ﹤0.01% 731
2019
Q2 		$1K Hold
2
– – ﹤0.01% 877
2019
Q1 		$1K Buy
+2
New +$1.19K ﹤0.01% 762

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CX Institutional's NKTR Position: Q4 2020 in Review

CX Institutional sold out of Nektar Therapeutics (NKTR) in Q4 2020, closing a stake of 5 shares — an estimated $1K sold.

CX Institutional first reported a position in NKTR in Q1 2019 and held it in 6 quarters. The position peaked at $2K in Q2 2020. 245 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.

  • CX Institutional reported no remaining Nektar Therapeutics position as of Q4 2020 after selling out during the quarter.
  • CX Institutional sold 5 Nektar Therapeutics shares in Q4 2020, an estimated $1K.
  • CX Institutional first reported a position in Nektar Therapeutics in Q1 2019 and held it in 6 quarters.
  • CX Institutional's Nektar Therapeutics position peaked at $2K in Q2 2020.
  • 245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.

Based on CX Institutional's 13F filing for Q4 2020, filed 12 Jan 2021.